The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

Peptide antigen-associated IgG levels were significantly lower in drug-naïve patients with first episode psychosis compared to control individuals.

This contract involves Da An Biotherapeutics supplying antibodies that LigaChem Biosciences will develop into ADC new drugs. The next-generation cancer treatment core technology, ADC, accurately ...

Oligonucleotide therapies are among the most promising biological therapeutics. They target disease at a different stage of ...

ADCs are composed of three components: a monoclonal antibody targeting a tumor-associated or tumor-specific antigen; a potent cytotoxic agent; and a linker that covalently binds the antibody with ...

Antibody-drug conjugates (ADCs) are typically made of an antibody covalently attached to a cytotoxic drug via either a permanent or labile linker, thus making a highly heterogeneous product. Some of ...

For decades, lab-made antibodies have been used to support patients fighting specific diseases. These treatments have become ...

Antibody-drug conjugates deliver chemotherapy by fusing a linker to a monoclonal antibody that attaches to a specific target expressed on cancer cells. Inside the cancer cell, a poisonous chemical ...

Recombinant antibodies are invented antibodies formed by using recombinant DNA technology. While traditional monoclonal ...

The theory behind antibody drug conjugates (ADCs) is simple yet elegant: by combining the specificity of a monoclonal antibody with the cytotoxicity of a potent small molecule drug, ADCs can ...